Differential downregulation of telomerase activity by bortezomib in multiple myeloma cells-multiple regulatory pathways in vitro and ex vivo

British Journal of Cancer

Volumn 107, Issue 11, 2012, Pages 1844-1852

  Weiss, C ^a   Uziel, O ^b   Wolach, O ^b   Nordenberg, J ^b   Beery, E ^b   Bulvick, S ^a   Kanfer, G ^b   Cohen, O ^b   Ram, R ^c,d   Bakhanashvili, M ^e   Magen Nativ, H ^c   Shilo, N ^d   Lahav, M ^b,d  

^a LANIADO HOSPITAL   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c Davidoff Cancer Center   (Israel)

^d RABIN MEDICAL CENTER   (Israel)

^e SHEBA MEDICAL CENTER   (Israel)

Author keywords

bortezomib; multiple myeloma; telomerase; telomerase regulation; telomere

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE;

ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; EX VIVO STUDY; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CELL LINE, TUMOR; CELL SURVIVAL; DNA METHYLATION; DOWN-REGULATION; HUMANS; MULTIPLE MYELOMA; PHOSPHORYLATION; PROMOTER REGIONS, GENETIC; PROTEIN KINASE C-ALPHA; PROTO-ONCOGENE PROTEINS C-AKT; PYRAZINES; TELOMERASE;

EID: 84870032381     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.460     Document Type: Article

References (37)

1. Akiyama M, Hideshima T, Hayashi T, Tai YT, Mitsiades CS, Mitsiades N, Chauhan D, Richardson P, Munshi NC, Anderson KC (2002) Cytokines modulate telomerase activity in a human multiple myeloma cell line. Cancer Res 62(13): 3876-3882
2. Akiyama M, Hideshima T, Shammas MA, Hayashi T, Hamasaki M, Tai YT, Richardson P, Gryaznov S, Munshi NC, Anderson KC (2003) Effects of oligonucleotide N3'-4P5' thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells. Cancer Res 63(19): 6187-6194
3. Anderson KC (2004) Bortezomib therapy for myeloma. Curr Hematol Rep 3(1): 65
4. Blackburn EH, Collins K (2010) Telomerase: an RNP enzyme synthesizes DNA. Cold Spring Harb Perspect Biol 3(5): pii: a003558
5. Cairney CJ, Keith WN (2008) Telomerase redefined: integrated regulation of hTR and hTERT for telomere maintenance and telomerase activity. Biochimie 90(1): 13-23
6. Chen KF, Yeh PY, Yeh KH, Lu YS, Huang SY, Cheng AL (2008) Downregulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells. Cancer Res 68(16): 6698-6707
7. Chen W, Dong Q, Shin KH, Kim RH, Oh JE, Park NH, Kang MK (2010) Grainyhead-like 2 enhances the hTERT gene expression by inhibiting DNA methylation at the 5'-CpG island in normal human keratinocytes. J Biol Chem 285(52): 40852-40863
8. Choi JH, Min NY, Park J, Kim JH, Park SH, Ko YJ, Kang Y, Moon YJ, Rhee S, Ham SW, Park AJ, Lee KH (2010) TSA-induced DNMT1 downregulation represses hTERT expression via recruiting CTCF into demethylated core promoter region of hTERT in HCT116. Biochem Biophys Res Commun 391(1): 449-454
9. David E, Sun SY, Waller EK, Chen J, Khuri FR, Lonial S (2005) The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT. Blood 106(13): 4322-4329
10. Dong CK, Masutomi K, Hahn WC (2005) Telomerase: regulation, function and transformation. Crit Rev Oncol Hematol 54(2): 85-93
11. Dong X, Liu A, Zer C, Feng J, Zhen Z, Yang M, Zhong L (2009) siRNA inhibition of telomerase enhances the anti-cancer effect of doxorubicin in breast cancer cells. BMC Cancer 9: 133-143
12. Gahrton G (2004) New therapeutic targets in multiple myeloma. Lancet 364(9446): 1648-1649
13. Hideshima T, Catley L, Yasui H, Ishitsuka K, Raje N, Mitsiades C, Podar K, Munshi NC, Chauhan D, Richardson PG, Anderson KC (2006) Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 107: 4053-4062
14. Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, Munshi N, Dang L, Castro A, Palombella V, Adams J, Anderson KC (2002) NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem 277(19): 16639-16647
15. Hideshima T, Ikeda H, Chauhan D, Okawa Y, Raje N, Podar K, Mitsiades C, Munshi NC, Richardson PG, Carrasco RD, Anderson KC (2009) Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood 114(5): 1046-1052
16. Jackson G, Einsele H, Moreau P, Miguel JS (2005) Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignancies. Cancer Treat Rev 31(8): 591-602
17. Kyle RA, Rajkumar SV (2009) Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 23(1): 3-9
18. Lenz HJ (2003) Clinical update: proteasome inhibitors in solid tumors. Cancer Treat Rev 29(suppl 1): 41-48
19. Li X, Ling W, Pennisi A, Khan S, Yaccoby S (2009) Fenretinide inhibits myeloma cell growth, osteoclastogenesis and osteoclast viability. Cancer Lett 284(2): 175-181
20. Liu S, Liu Z, Xie Z, Pang J, Yu J, Lehmann E, Huynh L, Vukosavljevic T, Takeki M, Klisovic RB, Baiocchi RA, Blum W, Porcu P, Garzon R, Byrd JC, Perrotti D, Caligiuri MA, Chan KK, Wu LC, Marcucci G (2008) Bortezomib induces DNA hypomethylation and silenced gene transcription by interfering with Sp1/NF-kappaB-dependent DNA methyltransferase activity in acute myeloid leukemia. Blood 111(4): 2364-2373
21. Matsui W, Huff CA, Wang Q, Malehorn MT, Barber J, Tanhehco Y, Smith BD, Civin CI, Jones RJ (2004) Characterization of clonogenic multiple myeloma cells. Blood 103(6): 2332-2336
22. Mor-Tzuntz R, Uziel O, Shpilberg O, Lahav J, Raanani P, Bakhanashvili M, Rabizadeh E, Zimra Y, Lahav M, Granot G (2010) Effect of imatinib on the signal transduction cascade regulating telomerase activity in K562 (BCR-ABL-positive) cells sensitive and resistant to imatinib. Exp Hematol 38(1): 27-37
23. Nomoto K, Maekawa M, Sugano K, Ushiama M, Fukayama N, Fujita S, Kakizoe T (2002) Methylation status and expression of human telomerase reverse transcriptase mRNA in relation to hypermethylation of the p16 gene in colorectal cancers as analyzed by bisulfite PCR-SSCP. Jpn J Clin Onco 32(1): 3-8
24. Oikonomou P, Messinis I, Tsezou A (2007) DNA methylation is not likely to be responsible for hTERT expression in premalignant cervical lesions. Exp Biol Med (Maywood) 232(7): 881-886
25. Panero J, Arbelbide J, Fantl DB, Rivello HG, Kohan D, Slavutsky I (2010) Altered mRNA expression of telomere-associated genes in monoclonal gammopathy of undetermined significance and multiple myeloma. Mol Med 16(11-12): 471-478
26. Ram R, Uziel O, Eldan O, Fenig E, Beery E, Lichtenberg S, Nordenberg Y, Lahav M (2009) Ionizing radiation up-regulates telomerase activity in cancer cell lines by post-translational mechanism via ras/phosphatidylinositol 3-kinase/Akt pathway. Clin Cancer Res 15(3): 914-923
27. Rafii A, Mirshahi P, Poupot M, Faussat A-M, Simon A, Ducros E, Mery E, Couderc B, Lis R, Capdet J, Bergalet J, Querleu D, Dagonnet F, Fournié J-J, Marie J-P, Pujade-Lauraine E, Favre G, Soria J, Mirshahi M (2008) Oncologic trogocytosis of an original stromal cells induces hemoresistance of ovarian tumours. PLoS ONE 3(12): e3894
28. Shammas MA, Koley H, Bertheau RC, Neri P, Fulciniti M, Tassone P, Blotta S, Protopopov A, Mitsiades C, Batchu RB, Anderson KC, Chin A, Gryaznov S, Munshi NC (2008) Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo. Leukemia 22(7): 1410-1418
29. Shay JW, Wright WE (2005) Mechanism-based combination telomerase inhibition therapy. Cancer Cell 7(1): 1-2
30. Shiratsuchi M, Muta K, Abe Y, Motomura S, Taguchi F, Takatsuki H, Uike N, Umemura T, Nawata H, Nishimura J (2002) Clinical significance of telomerase activity in multiple myeloma. Cancer 94(8): 2232-2238
31. Uziel O, Beery E, Dronichev V, Samocha K, Gryaznov S, Weiss L, Slavin S, Kushnir M, Nordenberg Y, Rabinowitz C, Rinkevich B, Zehavi T, Lahav M (2010) Telomere shortening sensitizes cancer cells to selected cytotoxic agents: in vitro and in vivo studies and putative mechanisms. PLoS One 5(2): e9132
32. Uziel O, Fenig E, Nordenberg J, Beery E, Reshef H, Sandbank J, Birenbaum M, Bakhanashvili M, Yerushalmi R, Luria D, Lahav M (2005) Imatinib mesylate (Gleevec) downregulates telomerase activity and inhibits proliferation in telomerase-expressing cell lines. Br J Cancer 92(10): 1881-1891
33. Wang JC, Bennett MR (2010) Nuclear factor-{kappa}B-mediated regulation of telomerase: the Myc link. Arterioscler Thromb Vasc Biol 30(12): 2327-2328
34. Wu KD, Orme LM, Shaughnessy Jr. J, Jacobson J, Barlogie B, Moore MA (2003) Telomerase and telomere length in multiple myeloma: correlations with disease heterogeneity, cytogenetic status, and overall survival. Blood 101(12): 4982-4989
35. Xu D, Zheng C, Bergenbrant S, Holm G, Björkholm M, Yi Q, Gruber A (2001) Telomerase activity in plasma cell dyscrasias. Br J Cancer 84(5): 621-625
36. Yaccoby S, Wezeman MJ, Henderson A, Cottler-Fox M, Yi Q, Barlogie B, Epstein J (2004) Cancer and the microenvironment: myeloma-osteoclast interactions as a model. Cancer Res 64(6): 2016-2023
37. Zöllinger A, Stühmer T, Chatterjee M, Gattenlöhner S, Haralambieva E, Müller-Hermelink HK, Andrulis M, Greiner A, Wesemeier C, Rath JC, Einsele H, Bargou RC (2008) Combined functional and molecular analysis of tumor cell signaling defines two distinct myeloma subgroups: Akt-dependent and Akt-independent multiple myeloma. Blood 112(8): 3403-3411